Market Overview

Sinovac Biotech Upgraded at Brean Murray

Sinovac Biotech (NASDAQ: SVA) is upgraded from Hold to Buy with a $5.50 price target at Brean Murray.

Posted-In: Upgrades Analyst Ratings

 

Related Articles (SVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters